From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Latest daily highlights
Dr Annelies Verbiest, a medical oncologist at the University Hospital of Antwerp, has presented noteworthy findings from the mini-oral sessions on non-prostate genitourinary tumours.
Two trials investigated an intravesical drug
Mounting evidence indicates a connection between breast cancer risk and outdoor air pollution, a link previously established for lung cancer. However, establishing this association for breast cancer has been challenging
In the context of the phase 2 SWOG S1801 trial, the efficacy of neoadjuvant-adjuvant administration of pembrolizumab was compared to adjuvant treatment alone, specifically focusing on the achievement of pathological
Two clinical trials were conducted to assess the role of radiotherapy in the treatment of locally advanced rectal cancer. In the CONVERT trial, neoadjuvant chemotherapy (nCT) with CAPOX alone was
Marco Gizzi, medical oncologist working at the Grand Hôpital de Charleroi and in Clinique Universitaires Saint-Luc, Brussels, had the privilege to present the highlights on prostate cancer during the ESMO
Laure-Anne Teuwen, a medical oncologist at the University Hospital of Antwerp, presents a selection of key studies in the field of gynaecological cancer discussed at ESMO 2023.
A phase II dose
Two investigations were presented concerning RAS-wildtype unresectable metastatic colon cancer, employing FOLFOXIRI treatment paired with the antibody therapy cetuximab.
The first, TRICE, was a randomized clinical trial comparing the chemotherapy
In the ADJORL1 study, the efficacy and safety of nivolumab were investigated as adjuvant therapy in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) following salvage surgery. All participants
The latest findings from the Survival Update of the DESTINY-Breast04 trial were presented, focusing on the comparison between trastuzumab deruxtecan (T-DXd) treatment and physician’s choice treatment in HER2-low unresectable/metastatic breast
The LIBRETTO-531 study was specifically structured to explore the optimal primary treatment approach for individuals diagnosed with advanced medullary thyroid carcinoma (MTC). The study involved a meticulous comparison between selpercatinib
Dr Mariana Brandao, a medical oncologist at the Clinic of Thoracic Oncology at the Institute Jules Bordet in Brussels, provided insights into various mini-oral presentations focusing on non-metastatic NSCLC.
In the
The FLAURA2 trial, where initial data unveiled at the World Lung Conference showed that integrating chemotherapy into the standard care for EGFR-mutated patients significantly enhanced progression-free survival (PFS) by approximately
Prof Dr Els Van Nieuwenhuysen presents the latest findings from the proffered paper session at ESMO23.
The FLAMES study, a phase 3 investigation involving randomized controlled patients afflicted with advanced
The KEYNOTE-585 and MATTERHORN studies delve into the role of adjuvant and neoadjuvant treatment involving checkpoint inhibitors in gastric cancer. Both trials randomise patients into groups undergoing chemotherapy before and
During the session, updated findings from the BEGONIA trial were unveiled, centering on an investigation into the effectiveness of a novel TROP2-directed Antibody Drug Conjugate (ADC) named datopotamab deruxtecan (Dato-DXd)
The advanTIG trial aimed to assess the impact of adding ociperlimab (OCI) to the standard care regimen of tislelizumab (TIS) + BAT1706 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma. The
The GORTEC 2014-04 trial sought to assess the efficacy of omitting chemotherapy after Stereotactic Ablative Radiotherapy (SABR) in first-line treatment for metastatic head and neck cancer patients. The study enrolled
Dr. Pierre Frères, a medical oncologist at CHU de Liège, provided an overview of the genitourinary tumors session at ESMO2023.
In the Phase 3 THOR-2 study, erdafitinib was compared to pembrolizumab
Professor Els Wauters, a respiratory oncologist at the University Hospital Leuven, discusses the proffered paper sessions of ESMO2023 in Madrid.
In the phase 3 SAPPHIRE trial, researchers investigated the impact
Professor Jean-François Baurain is pleased to provide a summary and analysis of the presentations from the mini-oral session on melanomas at ESMO2023.
The SECOMBIT trial assessed the efficacy of immunotherapy in
Prof Neven from KU Leuven reports on the proferred papers on early stage Breast Cancer that were reported the first day of the congress.
The first presentation by Prof Nadia Harbeck
In the field of non-metastatic non-small cell lung cancer (NSCLC), Professor Lore Decoster, a medical oncologist at UZ Brussels, made a selection of abstracts presented during the proffered session on
Dr. Emmanuel Seront, medical oncologist at Clinique Universitaire Saint-Luc, discussed the findings presented in the proffered paper session on renal cancer.
The randomized open-label Phase 3 LITESPARK-005 study compared the
Daily highlights
In-depth stories
Poster selection
With the educational support of:
